-
1
-
-
34249930520
-
Utility of free IGF-I measurements
-
Frystyk J (2007) Utility of free IGF-I measurements. Pituitary 10(2): 181-187
-
(2007)
Pituitary
, vol.10
, Issue.2
, pp. 181-187
-
-
Frystyk, J.1
-
2
-
-
77956665243
-
L, Paz-Ares LG, Karp DD, Lee AV (2010a) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor i receptor inhibition
-
Garland
-
Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV (2010a) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16(18): 4654-4665
-
Clin Cancer Res
, vol.16
, Issue.18
, pp. 4654-4665
-
-
Gualberto, A.1
Dolled-Filhart, M.2
Gustavson, M.3
Christiansen, J.4
Wang, Y.F.5
Hixon, M.L.6
Reynolds, J.7
McDonald, S.8
Ang, A.9
Rimm, D.L.10
Langer, C.J.11
Blakely, J.12
-
3
-
-
78650858388
-
Pre-treatment levels of circulating free IGF-1 identity NSCLC patients who derive clinical benefit from figitumumab
-
Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN (2010b) Pre-treatment levels of circulating free IGF-1 identity NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74
-
(2010)
Br J Cancer
, vol.104
, pp. 68-74
-
-
Gualberto, A.1
Hixon, M.L.2
Karp, D.D.3
Li, D.4
Green, S.5
Dolled-Filhart, M.6
Paz-Ares, L.G.7
Novello, S.8
Blakely, J.9
Langer, C.J.10
Pollak, M.N.11
-
4
-
-
33751076856
-
The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer
-
Han JY, Choi BG, Choi JY, Lee SY, Ju SY (2006) The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54(2): 227-234
-
(2006)
Lung Cancer
, vol.54
, Issue.2
, pp. 227-234
-
-
Han, J.Y.1
Choi, B.G.2
Choi, J.Y.3
Lee, S.Y.4
Ju, S.Y.5
-
5
-
-
77956227862
-
Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)
-
Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol (Meet Abstr) 28(Suppl 15): 7500
-
(2010)
J Clin Oncol (Meet Abstr
, Issue.28 SUPPL. 15
, pp. 7500
-
-
Jassem, J.1
Langer, C.J.2
Karp, D.D.3
Mok, T.4
Benner, R.J.5
Green, S.J.6
Park, K.7
Novello, S.8
Strausz, J.9
Gualberto, A.10
-
6
-
-
66349091290
-
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
-
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein Jr G, Johnson FM, Green S, Gualberto A (2009a) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15): 2516-2522
-
(2009)
J Clin Oncol
, vol.27
, Issue.15
, pp. 2516-2522
-
-
Karp, D.D.1
Paz-Ares, L.G.2
Novello, S.3
Haluska, P.4
Garland, L.5
Cardenal, F.6
Blakely, L.J.7
Eisenberg, P.D.8
Langer, C.J.9
Blumenschein Jr., G.10
Johnson, F.M.11
Green, S.12
Gualberto, A.13
-
7
-
-
70449556274
-
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin
-
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A (2009b) Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 4(11): 1397-1403
-
(2009)
J Thorac Oncol
, vol.4
, Issue.11
, pp. 1397-1403
-
-
Karp, D.D.1
Pollak, M.N.2
Cohen, R.B.3
Eisenberg, P.D.4
Haluska, P.5
Yin, D.6
Lipton, A.7
Demers, L.8
Leitzel, K.9
Hixon, M.L.10
Terstappen, L.W.11
Garland, L.12
Paz-Ares, L.G.13
Cardenal, F.14
Langer, C.J.15
Gualberto, A.16
-
8
-
-
49249125421
-
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
-
Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26(19): 3196-3203
-
(2008)
J Clin Oncol
, vol.26
, Issue.19
, pp. 3196-3203
-
-
Lacy, M.Q.1
Alsina, M.2
Fonseca, R.3
Paccagnella, M.L.4
Melvin, C.L.5
Yin, D.6
Sharma, A.7
Enriquez Sarano, M.8
Pollak, M.9
Jagannath, S.10
Richardson, P.11
Gualberto, A.12
-
9
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139
-
(2004)
N Engl J Med
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
10
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957
-
(2009)
N Engl J Med
, vol.361
, Issue.10
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
Sunpaweravong, P.7
Han, B.8
Margono, B.9
Ichinose, Y.10
Nishiwaki, Y.11
Ohe, Y.12
Yang, J.J.13
Chewaskulyong, B.14
Jiang, H.15
Duffield, E.L.16
Watkins, C.L.17
Armour, A.A.18
Fukuoka, M.19
-
11
-
-
77955049754
-
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study
-
Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS (2010) The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 103(3): 332-339
-
(2010)
Br J Cancer
, vol.103
, Issue.3
, pp. 332-339
-
-
Molife, L.R.1
Fong, P.C.2
Paccagnella, L.3
Reid, A.H.4
Shaw, H.M.5
Vidal, L.6
Arkenau, H.T.7
Karavasilis, V.8
Yap, T.A.9
Olmos, D.10
Spicer, J.11
Postel-Vinay, S.12
Yin, D.13
Lipton, A.14
Demers, L.15
Leitzel, K.16
Gualberto, A.17
De Bono, J.S.18
-
12
-
-
34249049000
-
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib
-
Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13(9): 2795-2803
-
(2007)
Clin Cancer Res
, vol.13
, Issue.9
, pp. 2795-2803
-
-
Morgillo, F.1
Kim, W.Y.2
Kim, E.S.3
Ciardiello, F.4
Hong, W.K.5
Lee, H.Y.6
-
13
-
-
77956571417
-
Targeting insulin-like growth factor signaling: Rational combination strategies
-
Olmos D, Basu B, de Bono JS (2010a) Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther 9(9): 2447-2449
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.9
, pp. 2447-2449
-
-
Olmos, D.1
Basu, B.2
De Bono, J.S.3
-
14
-
-
75249097799
-
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study
-
Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P (2010b) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11(2): 129-135
-
(2010)
Lancet Oncol
, vol.11
, Issue.2
, pp. 129-135
-
-
Olmos, D.1
Postel-Vinay, S.2
Molife, L.R.3
Okuno, S.H.4
Schuetze, S.M.5
Paccagnella, M.L.6
Batzel, G.N.7
Yin, D.8
Pritchard-Jones, K.9
Judson, I.10
Worden, F.P.11
Gualberto, A.12
Scurr, M.13
De Bono, J.S.14
Haluska, P.15
-
15
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
16
-
-
15844394554
-
Insulin-like growth factor expression in human cancer cell lines
-
DOI 10.1074/jbc.271.19.11477
-
Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F (1996) Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271(19): 11477-11483 (Pubitemid 26155990)
-
(1996)
Journal of Biological Chemistry
, vol.271
, Issue.19
, pp. 11477-11483
-
-
Quinn, K.A.1
Treston, A.M.2
Unsworth, E.J.3
Miller, M.-J.4
Vos, M.5
Grimley, C.6
Battey, J.7
Mulshine, J.L.8
Cuttitta, F.9
-
17
-
-
77953973648
-
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
-
Ulanet DB, Ludwig DL, Kahn CR, Hanahan D (2010) Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107(24): 10791-10798
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.24
, pp. 10791-10798
-
-
Ulanet, D.B.1
Ludwig, D.L.2
Kahn, C.R.3
Hanahan, D.4
-
18
-
-
0033585421
-
Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
-
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91(2): 151-156
-
(1999)
J Natl Cancer Inst
, vol.91
, Issue.2
, pp. 151-156
-
-
Yu, H.1
Spitz, M.R.2
Mistry, J.3
Gu, J.4
Hong, W.K.5
Wu, X.6
|